Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joanna Schmidt

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancer Research|February 18, 2010
HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferationAnjali Jain, Elicia Penuel, Sheldon Mink, et al.
Molecular Cancer|September 21, 2012
Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft modelsAngela Coxon, Beth Ziegler, Stephen Kaufman, et al.
Journal for Immunotherapy of Cancer|October 30, 2024
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinomaRicardo DeAzevedo, Madeline Steiner, Broderick X Turner, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 16, 2019
Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer ModelsYoungsoo Kim, Minji Jo, Joanna Schmidt, et al.
Cancers|January 21, 2023
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor SignalingFabiola Cecchi, Karen Rex, Joanna Schmidt, et al.
Molecular Cancer Therapeutics|March 14, 2012
Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibitionKian Kani, Vitor M Faca, Lindsey D Hughes, et al.
Plos One|July 18, 2013
Sphingosine kinase activity is not required for tumor cell viabilityKaren Rex, Shawn Jeffries, Matthew L Brown, et al.
Science Translational Medicine|November 20, 2015
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancerDavid Hong, Razelle Kurzrock, Youngsoo Kim, et al.
Journal for Immunotherapy of Cancer|November 18, 2018
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J Reilley, Patricia McCoon, Carl Cook, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer Research|February 18, 2010
HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferationAnjali Jain, Elicia Penuel, Sheldon Mink, et al.
Molecular Cancer|September 21, 2012
Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft modelsAngela Coxon, Beth Ziegler, Stephen Kaufman, et al.
Journal for Immunotherapy of Cancer|October 30, 2024
Type I MET inhibitors cooperate with PD-1 blockade to promote rejection of hepatocellular carcinomaRicardo DeAzevedo, Madeline Steiner, Broderick X Turner, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 16, 2019
Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer ModelsYoungsoo Kim, Minji Jo, Joanna Schmidt, et al.
Cancers|January 21, 2023
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor SignalingFabiola Cecchi, Karen Rex, Joanna Schmidt, et al.
Molecular Cancer Therapeutics|March 14, 2012
Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibitionKian Kani, Vitor M Faca, Lindsey D Hughes, et al.
Plos One|July 18, 2013
Sphingosine kinase activity is not required for tumor cell viabilityKaren Rex, Shawn Jeffries, Matthew L Brown, et al.
Science Translational Medicine|November 20, 2015
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancerDavid Hong, Razelle Kurzrock, Youngsoo Kim, et al.
Journal for Immunotherapy of Cancer|November 18, 2018
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J Reilley, Patricia McCoon, Carl Cook, et al.
Pageof 1